If wishes were horses, companies would IPO
This article was originally published in Scrip
Executive Summary
Chairing a debate on the attractiveness of biotech IPOs, co-hosted by One Nucleus, the Cambridge-London biotech network , and Scrip Intelligence, it was surprising to see how divergent the views of participants were. Even though the experienced venture capitalists in the room argued passionately at why they no longer considered the initial public offerings as a relevant ambition for their portfolio companies they were unable to convince an audience composed mainly of start-up entrepreneurs.